Risk Minimization Activities and Measures of Effectiveness

Abstract

Get full access to this article

View all access options for this article.

References

European Medicines Agency. Guideline on good pharmacovigilance practices: module XVI—risk minimisation measures—selection of tools and effectiveness indicators. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162051.pdf. Accessed July 25, 2014.

McGivney

Meyer

Duncan-Hewitt

. Medication therapy management: its relationship to patient counseling, disease management, and pharmaceutical care. J Am Pharm Assoc. 2007;47 (5):620–628.

Vinker

Eliyahu

Yaphe

. The effect of drug information leaflets on patient behavior. Isr Med Assoc J. 2007;9 (5):383–386.

Wolf

King

Wilson

. Usability of FDA-approved medication guides. J Gen Intern Med. 2012;27 (12):1714–1720.

US Food and Drug Administration. Guidance for industry. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products—content and format. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm075096.pdf. Accessed July 25, 2014.

European Medicines Agency. A guideline on summary of product characteristics. Available at: http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. Accessed July 25, 2014.

Pander Maat

Lentz

. Improving the usability of patient information leaflets. Patient Educ Couns. 2010;80 (1):113–119.